Ladenburg Thalmann Financial Services’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-300	Closed	-$4K	–	5504
2019 Q1	$4K	Buy	+300	New	+$3.42K	﹤0.01%	4784
2017 Q2	–	Sell	-28	Closed	-$1K	–	5025
2017 Q1	$1K	Sell	28 -35	-56%	-$1.54K	﹤0.01%	4782
2016 Q4	$3K	Sell	63 -160	-72%	-$8.41K	﹤0.01%	4469
2016 Q3	$12K	Buy	223 +1	+0.5%	+$48	﹤0.01%	3730
2016 Q2	$9K	Buy	222 +148	+200%	+$6.44K	﹤0.01%	3856
2016 Q1	$3K	Buy	+74	New	+$2.54K	﹤0.01%	4299

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ladenburg Thalmann Financial Services's FPRX Position: Q2 2019 in Review

Ladenburg Thalmann Financial Services sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2019, closing a stake of 300 shares — an estimated $4K sold.

Ladenburg Thalmann Financial Services first reported a position in FPRX in Q1 2016 and held it in 6 quarters. The position peaked at $12K in Q3 2016. 114 funds tracked by Wall St. Rank hold FPRX as of Q2 2019.

Ladenburg Thalmann Financial Services reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 300 Five Prime Therapeutics, Inc. shares in Q2 2019, an estimated $4K.
Ladenburg Thalmann Financial Services first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 6 quarters.
Ladenburg Thalmann Financial Services's Five Prime Therapeutics, Inc. position peaked at $12K in Q3 2016.
114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q2 2019, filed 15 Aug 2019.